HSITF: AI 评分 44/100 — AI 分析 (4月 2026)

Hadasit Bio-Holdings Ltd is an Israeli biotechnology company focusing on developing therapeutics in oncology, regenerative medicine, and inflammatory diseases. Their lead product is ProtAb, an immunotherapeutic monoclonal antibody targeting autoimmune inflammatory conditions.

Key Facts: AI Score: 44/100 Sector: Healthcare

公司概况

概要：

Hadasit Bio-Holdings Ltd, based in Israel, operates within the biotechnology sector, concentrating on oncology, regenerative medicine, and inflammatory diseases. The company's primary focus is the development of ProtAb, an immunotherapeutic monoclonal antibody aimed at treating autoimmune inflammatory diseases, positioning it in a niche market with significant growth potential.

HSITF是做什么的？

Founded in 2005 and headquartered in Jerusalem, Israel, Hadasit Bio-Holdings Ltd is a biotechnology company dedicated to the discovery and development of innovative therapeutics. The company operates within the dynamic and competitive biotechnology industry, focusing on addressing unmet medical needs in oncology, regenerative medicine, and inflammatory diseases. Hadasit Bio-Holdings' core product is ProtAb, an immunotherapeutic monoclonal antibody designed for the treatment of autoimmune inflammatory diseases. ProtAb represents the company's commitment to developing targeted therapies that can improve patient outcomes. Hadasit Bio-Holdings operates primarily in Israel, engaging in research and development activities to advance its pipeline of therapeutic candidates. As a biotechnology company, Hadasit Bio-Holdings collaborates with research institutions and other industry partners to leverage scientific expertise and accelerate the development of its products. The company's small size, with only two employees, reflects its stage of development and focus on early-stage research and development activities. Hadasit Bio-Holdings aims to create value by identifying and developing promising therapeutic candidates, ultimately seeking partnerships or licensing agreements to bring its products to market.

HSITF的投资论点是什么？

Hadasit Bio-Holdings Ltd presents a high-risk, high-reward investment opportunity within the biotechnology sector. The company's focus on ProtAb, an immunotherapeutic monoclonal antibody for autoimmune inflammatory diseases, offers potential for significant returns if clinical trials are successful and regulatory approvals are obtained. However, the company's small size and limited resources pose challenges to its ability to advance its pipeline independently. Key value drivers include successful clinical trial outcomes for ProtAb, strategic partnerships with larger pharmaceutical companies, and potential licensing agreements. The company's negative P/E ratio of -2.03 reflects its current lack of profitability, underscoring the speculative nature of the investment. Investors should carefully consider the risks associated with investing in early-stage biotechnology companies before making any investment decisions.

HSITF在哪个行业运营？

Hadasit Bio-Holdings Ltd operates within the biotechnology industry, a sector characterized by rapid innovation, high risk, and significant potential for reward. The industry is driven by advancements in scientific research, increasing demand for novel therapies, and an aging global population. The competitive landscape includes established pharmaceutical companies, as well as numerous smaller biotechnology firms, all vying to develop and commercialize innovative treatments. Hadasit Bio-Holdings' focus on oncology, regenerative medicine, and inflammatory diseases aligns with key growth areas within the biotechnology industry. The company's success will depend on its ability to navigate the complex regulatory environment, secure funding, and effectively compete with larger, more established players.

Biotechnology

Healthcare

HSITF有哪些增长机遇？

Growth opportunity 1: Successful clinical trials for ProtAb represent a significant growth opportunity for Hadasit Bio-Holdings Ltd. Positive clinical trial results would validate the efficacy and safety of ProtAb, increasing its market potential and attracting potential partners. The market for autoimmune disease therapeutics is substantial, with a global market size estimated at billions of dollars. The timeline for clinical trials can vary, but typically involves several phases over multiple years. Successful completion of each phase would represent a major milestone for the company.
Growth opportunity 2: Strategic partnerships with larger pharmaceutical companies could provide Hadasit Bio-Holdings Ltd with access to funding, expertise, and resources needed to advance its pipeline. Collaborations with established players can accelerate the development and commercialization of ProtAb, increasing its market reach and potential revenue. The timeline for securing partnerships can vary, but typically involves negotiations and due diligence processes. Successful partnerships would significantly enhance the company's growth prospects.
Growth opportunity 3: Expansion into new therapeutic areas represents another growth opportunity for Hadasit Bio-Holdings Ltd. By leveraging its expertise in antibody development, the company could explore new applications for its technology platform in other disease areas. The market for novel therapeutics is constantly evolving, with new opportunities emerging as scientific understanding advances. The timeline for expanding into new therapeutic areas would depend on the company's research and development efforts.
Growth opportunity 4: Securing regulatory approvals for ProtAb in key markets, such as the United States and Europe, is essential for commercial success. Regulatory approvals would allow the company to market and sell ProtAb to a wider patient population, generating revenue and increasing its market share. The regulatory approval process can be lengthy and complex, requiring extensive clinical data and documentation. Successful regulatory approvals would represent a major milestone for the company.
Growth opportunity 5: Out-licensing or selling ProtAb to a larger pharmaceutical company could provide Hadasit Bio-Holdings Ltd with a significant upfront payment and ongoing royalties. This strategy would allow the company to monetize its intellectual property and generate returns for its investors. The timeline for out-licensing or selling ProtAb would depend on market conditions and the level of interest from potential acquirers. A successful transaction would provide the company with financial resources to pursue other opportunities.

Hadasit Bio-Holdings Ltd operates in the biotechnology industry, focusing on oncology, regenerative medicine, and inflammatory diseases.
The company's primary product is ProtAb, an immunotherapeutic monoclonal antibody for the treatment of autoimmune inflammatory diseases.
Hadasit Bio-Holdings Ltd was founded in 2005 and is based in Jerusalem, Israel.
The company has a market capitalization of $0.00B, indicating its small size and early stage of development.
The company's P/E ratio is -2.03, reflecting its current lack of profitability.

HSITF提供哪些产品和服务？

Develops immunotherapeutic monoclonal antibodies.
Focuses on treatments for autoimmune inflammatory diseases.
Conducts research and development in oncology.
Engages in regenerative medicine research.
Operates in the biotechnology industry in Israel.

HSITF如何赚钱？

Develops and patents novel therapeutic antibodies.
Out-licenses or partners with larger pharmaceutical companies for commercialization.
Generates revenue through licensing fees and royalties.

Pharmaceutical companies seeking novel therapeutic candidates.
Patients with autoimmune inflammatory diseases.
Healthcare providers treating autoimmune inflammatory diseases.

Proprietary antibody technology.
Patents protecting its intellectual property.
Expertise in antibody development and immunology.

什么因素可能推动HSITF股价上涨？

Upcoming: Clinical trial results for ProtAb could drive significant stock movement.
Upcoming: Potential partnerships with larger pharmaceutical companies could provide funding and expertise.
Upcoming: Regulatory approvals for ProtAb in key markets would expand market access.
Ongoing: Advancements in the company's research and development pipeline could lead to new therapeutic candidates.

HSITF的主要风险是什么？

Potential: Clinical trial failures could negatively impact the company's prospects.
Potential: Regulatory hurdles could delay or prevent the approval of ProtAb.
Ongoing: Competition from larger, more established companies could limit market share.
Ongoing: The company's small size and limited resources pose challenges to its ability to execute its strategy.
Ongoing: Dependence on a single product candidate (ProtAb) increases the company's vulnerability to setbacks.

HSITF的核心优势是什么？

Focus on innovative immunotherapeutic antibodies.
Potential for high-value licensing agreements.
Expertise in autoimmune inflammatory diseases.

HSITF的劣势是什么？

Small size and limited resources.
Dependence on a single product candidate (ProtAb).
Lack of profitability.

HSITF有哪些机遇？

Successful clinical trials for ProtAb.
Strategic partnerships with larger pharmaceutical companies.
Expansion into new therapeutic areas.

HSITF面临哪些威胁？

Clinical trial failures.
Regulatory hurdles.
Competition from larger, more established companies.

HSITF的竞争对手是谁？

Actimis Pharmaceuticals — Focuses on autoimmune and inflammatory diseases. — (ACMSY)
CalciMedica, Inc. — Develops therapies for acute and chronic inflammatory diseases. — (CLCS)
Corvus Pharmaceuticals, Inc. — Developing therapies for cancer and autoimmune diseases. — (CRVW)
Global BioLife Inc. — Focuses on developing and commercializing innovative healthcare products. — (GLABF)
Ares Acquisition Corporation — Specializes in acquiring companies in the healthcare sector. — (MRES)

Key Metrics

MoonshotScore: 44/100

Company Profile

CEO: Yuval Adar
Headquarters: Jerusalem, IL
Employees: 2
Founded: 2010

AI Insight

AI analysis pending for HSITF

OTC Tier: OTC Other
Disclosure Status: Unknown

常见问题

What does Hadasit Bio-Holdings Ltd do?

Hadasit Bio-Holdings Ltd is a biotechnology company based in Israel, focused on developing novel therapeutics in the areas of oncology, regenerative medicine, and inflammatory diseases. Their primary focus is on ProtAb, an immunotherapeutic monoclonal antibody designed to treat autoimmune inflammatory diseases. The company aims to develop and commercialize innovative treatments that address unmet medical needs in these therapeutic areas, ultimately improving patient outcomes through targeted therapies.

What do analysts say about HSITF stock?

As of 2026-03-18, there is no available analyst coverage for Hadasit Bio-Holdings Ltd (HSITF). This is likely due to the company's small market capitalization, OTC listing, and early stage of development. Investors should conduct their own thorough research and consider the risks associated with investing in small-cap biotechnology companies before making any investment decisions. The lack of analyst coverage underscores the speculative nature of the investment.

What are the main risks for HSITF?

Hadasit Bio-Holdings Ltd faces several key risks, including clinical trial failures, regulatory hurdles, competition from larger companies, and limited financial resources. Clinical trial failures could halt the development of ProtAb and negatively impact the company's prospects. Regulatory hurdles could delay or prevent the approval of ProtAb, limiting its market access. Competition from larger, more established companies could limit market share and pricing power. The company's small size and limited resources pose challenges to its ability to execute its strategy and compete effectively.